Xuanzhu Biopharmaceutical Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-34
RECRUITING2
READOUTS ≤12 MONTHS1
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| XZP-3287+Fulvestrant NCT05077449 |
P3 | Active, not recruiting | Advanced Breast Cancer | 300 | 2024-02-22 |
| XZP-5955 tablets NCT04996121 |
P1/2 | Recruiting | Locally Advanced or Metastatic Solid Tumors; Locally Advanced or Metastatic Non-small Cell Lung Cancer | 360 | 2025-09 |
| XZP-3287+ Letrozole/Anastrozole NCT05257395 |
P3 | Active, not recruiting | Advanced Breast Cancer | 397 | 2025-12-05 (+12 mo) |
| NCT07010107 NCT07010107 |
P3 | Recruiting | Reflux Esophagitis (RE) | 500 | 2026-04 |
| Anaprazole Sodium enteric-coated tablet NCT07606833 |
P3 | Not yet recruiting | HELICOBACTER PYLORI INFECTIONS | 556 | 2027-02-19 |